sorafenib has been researched along with calixarenes in 2 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (calixarenes) | Trials (calixarenes) | Recent Studies (post-2010) (calixarenes) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,903 | 0 | 1,088 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aguilar-Suárez, LE; Barroso-Flores, J; Galindo-Murillo, R | 1 |
| Che, CM; Fung, YME; Ko, FCF; Kwong, EML; Lai, CL; Leung, Z; Liu, BHM; Ma, APY; Mao, X; Ng, IO; Tey, SK; Wong, DKH; Yam, JWP | 1 |
2 other study(ies) available for sorafenib and calixarenes
| Article | Year |
|---|---|
A mixed DFT-MD methodology for the in silico development of drug releasing macrocycles. Calix and thia-calix[N]arenes as carriers for Bosutinib and Sorafenib.
Topics: Aniline Compounds; Calixarenes; Computer Simulation; Drug Carriers; Drug Liberation; Molecular Dynamics Simulation; Molecular Structure; Niacinamide; Nitriles; Phenylurea Compounds; Quantum Theory; Quinolines; Sorafenib | 2016 |
Galectin-1 promotes hepatocellular carcinoma and the combined therapeutic effect of OTX008 galectin-1 inhibitor and sorafenib in tumor cells.
Topics: Animals; Calixarenes; Carcinoma, Hepatocellular; Galectin 1; Humans; Liver Neoplasms; Male; Mice; Mice, Nude; Sorafenib; Transfection | 2019 |